Balyasny Asset Management LLC Lineage Cell Therapeutics, Inc. Transaction History

Balyasny Asset Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$1.2 - $1.53 $39,146 - $49,911	32,622 Added 137.41%	56,362 $84,000
Q4 2022 Feb 14, 2023	BUY	$1.02 - $1.5 $24,214 - $35,610	23,740 New	23,740 $27,000
Q2 2022 Aug 15, 2022	BUY	$1.12 - $1.61 $11,683 - $16,795	10,432 New	10,432 $16,000
Q2 2021 Aug 16, 2021	SELL	$2.17 - $3.0 $78,471 - $108,486	-36,162 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$1.77 - $3.1 $64,006 - $112,102	36,162 New	36,162 $85,000

120

94.2M

63.8K

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $91.7M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.